Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study ; volume:83 ; number:1 ; year:2020 ; pages:25-33
European neurology ; 83, Heft 1 (2020), 25-33

Urheber
Meca-Lallana, José
Ayuso, Teresa
Martínez-Yelamos, Sergio
Durán, Carmen
Contreras Martín, Yessica
Herrera Navarro, Nicolás
Pérez Sempere, Angel
Álvarez-Cermeño, Jose C.
Millán !1261032489!
Meca-Lallana, Virginia
Romero Sevilla, Raúl
Ricart, Javier

DOI
10.1159/000505778
URN
urn:nbn:de:101:1-2020052800193651900615
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
11.08.2025, 02:50 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Meca-Lallana, José
  • Ayuso, Teresa
  • Martínez-Yelamos, Sergio
  • Durán, Carmen
  • Contreras Martín, Yessica
  • Herrera Navarro, Nicolás
  • Pérez Sempere, Angel
  • Álvarez-Cermeño, Jose C.
  • Millán !1261032489!
  • Meca-Lallana, Virginia
  • Romero Sevilla, Raúl
  • Ricart, Javier

Ähnliche Objekte (12)

Second-line Therapien bei malignen biliären Tumoren

Second-line Therapien bei malignen biliären Tumoren

Sirolimus as a second-line treatment for Graves’ orbitopathy

Sirolimus as a second-line treatment for Graves’ orbitopathy

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Medication beliefs in first-line and second-line treated multiple sclerosis patients

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Adverse Drug Reactions with First-Line and Second-Line Drugs in Treatment of Tuberculosis

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014–2016)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Trabectedin as second-line treatment in metastatic myxoid liposarcoma: a case report

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Congenital tuberculosis (TB) use of second-line medication and therapeutic drug monitoring

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics

Verbundene Objekte